22480-88-2 Usage
Uses
Used in Pharmaceutical Industry:
METHYL-2,3,4-TRIMETHOXYPHENYLACETATE is used as a key intermediate for the synthesis of lespeflorin I1 and psoralidin derivatives. These compounds are known for their anticancer properties, making METHYL-2,3,4-TRIMETHOXYPHENYLACETATE an essential component in the development of novel cancer treatments.
Application Reason:
The use of METHYL-2,3,4-TRIMETHOXYPHENYLACETATE in the pharmaceutical industry is primarily due to its role in the synthesis of lespeflorin I1 and psoralidin derivatives. These derivatives have demonstrated potential anticancer properties, making them valuable candidates for the development of new cancer therapies. By serving as an intermediate in their production, METHYL-2,3,4-TRIMETHOXYPHENYLACETATE plays a crucial role in advancing cancer research and treatment options.
Check Digit Verification of cas no
The CAS Registry Mumber 22480-88-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,2,4,8 and 0 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 22480-88:
(7*2)+(6*2)+(5*4)+(4*8)+(3*0)+(2*8)+(1*8)=102
102 % 10 = 2
So 22480-88-2 is a valid CAS Registry Number.
22480-88-2Relevant academic research and scientific papers
Synthesis of Psoralidin derivatives and their anticancer activity: First synthesis of Lespeflorin I1
Pahari, Pallab,Saikia, Ujwal Pratim,Das, Trinath Prasad,Damodaran, Chendil,Rohr, Jürgen
, p. 3324 - 3334 (2016/05/19)
Synthetic scheme for the preparation of a number of different derivatives of anticancer natural product Psoralidin is described. A convergent synthetic approach is followed using simple starting materials like substituted phenyl acetic esters and benzoic acids. The developed synthetic route leads us to complete the first synthesis of an analogous natural product Lespeflorin I1, a mild melanin synthesis inhibitor. Preliminary bioactivity studies of the synthesized compounds are carried out against two commonly used prostate cancer cell lines. Results show that the bioactivity of the compounds can be manipulated by the simple modification of the functional groups.
